#1 Clinical Trials Search in Europe

Cemiplimab

Cemiplimab is an innovative immunotherapy drug being studied in clinical trials for the treatment of various advanced skin cancers, including cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). This article explores the use of cemiplimab in clinical trials, its potential benefits, and what patients can expect from this emerging treatment option.

Table of Contents

What is Cemiplimab?

Cemiplimab, also known by its brand name Libtayo or research codes REGN2810 and SAR439684, is a type of medication called an immunotherapy drug[1][2]. It belongs to a class of drugs known as immune checkpoint inhibitors, which help the body’s immune system fight cancer[3].

How Does Cemiplimab Work?

Cemiplimab works by targeting a protein called PD-1 (programmed cell death 1) on immune cells. By blocking PD-1, cemiplimab helps activate the immune system to recognize and attack cancer cells[4]. This mechanism is particularly effective against cancers with a high number of mutations, such as certain skin cancers[3].

What Conditions Does Cemiplimab Treat?

Cemiplimab is primarily used to treat advanced forms of skin cancer, including:

  • Cutaneous Squamous Cell Carcinoma (CSCC): A type of skin cancer that develops in the squamous cells of the skin’s outer layers[1][3]
  • Basal Cell Carcinoma (BCC): Another type of skin cancer that begins in the basal cells of the skin[5]
  • Locally Advanced or Metastatic Skin Cancers: These are cancers that have spread to nearby tissues or other parts of the body[6]

Research is also ongoing to evaluate cemiplimab’s effectiveness in treating other conditions, such as:

  • HPV-Related Squamous Cell Carcinoma: A type of cancer caused by human papillomavirus, often affecting the head and neck region[7]
  • Mycosis Fungoides: A type of cutaneous T-cell lymphoma, which is a cancer of the immune system that affects the skin[4]
  • Angiosarcoma: A rare cancer that develops in the inner lining of blood vessels and lymph vessels[6]

How is Cemiplimab Administered?

Cemiplimab is typically given as an intravenous (IV) infusion. The standard dose is 350 mg administered every 3 weeks[1][3]. Treatment duration can vary depending on the specific condition and treatment plan, but it may continue for up to 2 years in some cases[6].

How Effective is Cemiplimab?

Clinical trials have shown promising results for cemiplimab in treating advanced skin cancers:

  • In patients with advanced CSCC, cemiplimab has shown overall response rates (ORR) of around 46-47%[3]
  • Many patients experience rapid and durable tumor reductions[3]
  • Some patients have achieved complete responses (total disappearance of tumors)[3]

It’s important to note that response to treatment can vary among individuals, and ongoing research continues to evaluate cemiplimab’s effectiveness in different scenarios and cancer types.

What Are the Side Effects of Cemiplimab?

Like all medications, cemiplimab can cause side effects. Common side effects may include:

  • Fatigue
  • Rash
  • Diarrhea
  • Nausea
  • Joint pain (arthralgia)
  • Hypothyroidism (underactive thyroid)[3]

More serious side effects, known as immune-related adverse events (irAEs), can occur as the immune system becomes more active. These can affect various organs and may require prompt medical attention[5].

Ongoing Research and Future Directions

Numerous clinical trials are currently underway to further explore the potential of cemiplimab:

  • Testing cemiplimab in combination with other treatments, such as chemotherapy[7]
  • Evaluating its use before surgery (neoadjuvant) and after surgery (adjuvant) in various cancers[3][1]
  • Investigating biomarkers that may predict response to treatment[8]
  • Assessing its effectiveness in different stages of cancer and in combination with other therapies[7]

These ongoing studies aim to optimize the use of cemiplimab and potentially expand its applications to benefit more patients with various types of cancer.

Aspect Details
Drug Name Cemiplimab (also known as REGN2810, Libtayo)
Drug Type PD-1 inhibitor immunotherapy
Primary Cancers Studied Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma (BCC)
Other Cancers Studied Angiosarcomas, Mycosis Fungoides, HPV-related Head and Neck Cancer
Common Administration 350 mg intravenous infusion every 3 weeks
Key Outcome Measures Objective Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS), Pathologic Complete Response (pCR)
Safety Monitoring Immune-related Adverse Events (irAEs), Infusion-related Reactions
Unique Approaches Neoadjuvant therapy, Intralesional injections, Combination with chemotherapy

FAQ

  • What is cemiplimab and how does it work? Cemiplimab is an immunotherapy drug known as a PD-1 inhibitor. It works by blocking a protein called PD-1 on immune cells, which helps the immune system recognize and attack cancer cells more effectively.
  • What types of skin cancer is cemiplimab being studied for? Cemiplimab is primarily being studied for advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). Some trials are also investigating its use in other skin cancers like angiosarcomas and mycosis fungoides.
  • How is cemiplimab administered in clinical trials? In most trials, cemiplimab is given as an intravenous (IV) infusion every 3 weeks. The typical dose is 350 mg, though some trials are exploring different dosing schedules or methods of administration, such as intralesional injections.
  • What are the potential benefits of cemiplimab treatment? Clinical trials are investigating cemiplimab's ability to shrink tumors, slow disease progression, and improve survival in patients with advanced skin cancers. Some studies have shown promising response rates and durable responses in patients who have limited treatment options.
  • What are the possible side effects of cemiplimab? Common side effects may include fatigue, skin rash, and diarrhea. As an immunotherapy, cemiplimab can also cause immune-related adverse events affecting various organs. Patients in trials are closely monitored for these potential side effects.

Ongoing Clinical Trials on Cemiplimab

  • Study of Tuvusertib and Cemiplimab for Patients with Non-Squamous Non-Small Cell Lung Cancer After Previous Treatments

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Italy Spain

  • Study of Cemiplimab for Patients with Stage II to IV Cutaneous Squamous Cell Carcinoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Re-Challenging Advanced Lung Cancer with Cemiplimab After Initial Treatment with Ipilimumab and Radiotherapy

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety and Effectiveness of REGN7075 and Cemiplimab, with or without Chemotherapy, for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1
    Investigated drugs:
    France The Netherlands Poland Spain

Glossary

  • Cutaneous Squamous Cell Carcinoma (CSCC): A type of skin cancer that develops in the squamous cells of the outer layers of the skin. It is the second most common form of skin cancer.
  • Basal Cell Carcinoma (BCC): The most common type of skin cancer, which develops in the basal cells of the skin's outer layer (epidermis).
  • PD-1 inhibitor: A type of immunotherapy drug that blocks the PD-1 protein on immune cells, helping to boost the immune system's ability to fight cancer.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Immune-related Adverse Events (irAEs): Side effects that occur when the immune system becomes overactive due to immunotherapy, potentially affecting various organs in the body.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Pathologic Complete Response (pCR): The absence of all signs of cancer in tissue samples removed during surgery or biopsy after treatment.

References

  1. https://clinicaltrials.eu/trial/study-of-cemiplimab-for-patients-with-stage-ii-to-iv-cutaneous-squamous-cell-carcinoma/
  2. https://clinicaltrials.gov/study/NCT05302297
  3. https://clinicaltrials.eu/trial/study-on-cemiplimab-for-patients-with-high-risk-stage-iii-iv-cutaneous-squamous-cell-carcinoma/
  4. https://clinicaltrials.gov/study/NCT05538988
  5. https://clinicaltrials.gov/study/NCT03836105
  6. https://clinicaltrials.gov/study/NCT04873375
  7. https://clinicaltrials.gov/study/NCT04988074
  8. https://clinicaltrials.gov/study/NCT05878288